Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP standards for infant formula

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Pharmacopeia proposes adding to the Food Chemicals Codex three nucleotides found in breast milk and commonly added to infant formula, and two DHA oils. USP will add the new voluntary industry standards to the codex following a three-month public comment period ending March 31 to enhance the quality and safety of infant formulas and functional foods. The proposed nucleotide standards - for disodium 5'-uridylate, 5'-adenylic acid and 5'-cytidylic acid - designate the identity, purity and impurities of the ingredients and validated test methods, USP says. The proposed DHA standards are for DHA algal oil, crypthecodinium type and DHA algal oil, schizochytrium type. During a Jan. 14 interview, USP Director of Food Standards Markus Lipp said the standards allow marketers to approach suppliers with a set of minimum requirements for products, and allow suppliers to promote their adherence to the standards to set themselves apart from competitors

You may also be interested in...



Patient Voice Makes Impact In Scientific Advice From EU HTA Network

The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.

MSF Wants Faster Deployment Of Ebola Vaccine At ‘Fair’ Price

As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks. 

Deals Shaping The Medical Industry, December 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.

Topics

UsernamePublicRestriction

Register

PS103716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel